ProMIS Neurosciences Inc. Annual Report - How They Did This Year

I’m writing this guide to help you understand how ProMIS Neurosciences performed this year. Instead of digging through dense legal filings, we’ll break down what’s happening at the company so you can decide if it fits your investment goals.

1. What does this company do?

ProMIS is a biotech company developing precision antibody treatments for neurodegenerative diseases like Alzheimer’s, ALS, and Multiple Sclerosis. They are in the research phase, meaning they have no products on the market yet.

They are currently prioritizing PMN310, an antibody designed to target toxic proteins that drive Alzheimer’s. Their other projects include PMN442 and PMN267, which target proteins linked to ALS and dementia.

2. Financial Performance & Health

ProMIS is not yet profitable and generates no sales revenue. For the year ending December 31, 2024, the company lost approximately $23.8 million, up from a $14.2 million loss in 2023. This increase reflects higher spending on clinical trials and research. As of year-end, they held about $14.5 million in cash.

Because they have no product sales, they rely entirely on raising money from investors. In 2024, they used stock offerings to fund operations, including a $30.4 million private placement. While these raises keep the company running, they also issue more shares, which reduces your ownership percentage and the potential value of your existing shares.

3. Major Wins and Challenges

• The "Cash Runway" Strategy: Management has enough cash to operate through the second half of 2025. This money is dedicated to the ongoing Phase 1a trial of PMN310, which tests the drug’s safety in healthy volunteers.
• The Challenge: The company faces significant operational risks. They rely on outside partners to manage clinical trials and manufacture their drugs. Any delays in patient enrollment or manufacturing errors could stall their progress. This might force the company to seek emergency funding on unfavorable terms.

4. Future Outlook & Risks

The future of ProMIS depends entirely on the results of the PMN310 trial.

• The Upside: If PMN310 proves safer than current Alzheimer’s treatments—which often cause brain swelling—the company becomes a prime target for a buyout or partnership with a larger pharmaceutical firm.
• The Risk: This is a high-risk investment. Clinical trials often fail when moving from early to later stages. Even if the science works, the FDA may demand more expensive, long-term studies. Because the company spends roughly $2 million to $2.5 million per month, they will likely need to raise more money by late 2025. This will almost certainly lead to more shares being issued, further reducing your ownership stake.

Bottom Line: You aren't buying a company with steady profits. You are betting on their ability to solve difficult brain diseases. If you invest, expect extreme price swings and the high probability of future share offerings until the company hits a major milestone.